50 results about "Long chain triglyceride" patented technology

The present invention relates to a water-free pharmaceutical composition comprising one or more local anaesthetics in base form and which is suitable for topical administration. The composition further comprises a lipid vehicle comprising long-chain triglycerides (LCT) and at least 10 % by weight of medium-chain monoglycerides (MCM) selected so the composition has an at least semi-solid appearance at the body temperature at the site of administration. The invention further relates to methods of producing and sterilizing the compositions.

The invention discloses a method for preparing medium- and long-chain triglyceride by virtue of a packed bed reactor, and belongs to the technical field of oil deep processing and modification. Medium-chain fatty acid triglyceride and oil undergo transesterification as raw materials to prepare medium- and long-chain triglyceride in the packed bed reactor under the 1,3-specific immobilized enzyme catalyzing transesterification capable of catalyzing transesterification reaction; then a transesterification product is subjected to ethanol extraction to obtain a high-purity medium- and long-chain triglyceride product; a residual product after extraction can be repacked into the reactor to continue participating in preparation of medium- and long-chain triglyceride of the next batch as a raw material. According to the method, time for reaction in the packed bed reactor can be remarkably shortened to 15 to 60 minutes from original 4 hours for stirring reaction for the preparation of the medium- and long-chain triglyceride, and reaction efficiency is improved; the product with medium- and long-chain fatty acid triglyceride content of not lower than 75 percent can be stably prepared by simple transesterification reaction and subsequent ethanol extraction.

Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides.

Cosmetic particle compositions are provided which are adapted to form hard cosmetic particles that transform to soft cosmetic particles after their incorporation into topical formulations, particularly surfactant-based topical formulations. The composition includes one or more partially or fully hydrogenated triglyceride oils, at least 50% of which have at least 15% by weight fatty acid moieties with carbon chain lengths of C18 or higher. Additives may be disposed in or on the hard cosmetic particles and delivered when the cosmetic particles are broken proximate a target such as the skin, hair or nails of a mammalian subject or another target. The transformable hard cosmetic particles permit the storage and shipment of intact cosmetic particles yet transform in situ to achieve the benefits of soft cosmetic particles.

The present disclosure provides a pharmaceutically acceptable, stable, and optically clear oil-in-water nanoemulsions (intensity-averaged diameter<100 nm) with an oil phase comprising>10% w / v of long chain triglyceride, total surfactant and cosurfactant concentration less than that of oil phase and without the use of alcohol as cosolvent in the aqueous phase. The nanoemulsions of this disclosure have extremely favorable particle size distribution, optical clarity, and product stability against Ostwald ripening with high levels of oil concentrations. Poorly water soluble, therapeutically active agents and others can be incorporated in the nanoemulsion systems to improve their solubility / stability in aqueous medium or to enhance their delivery for use in pharmaceutical, food, cosmetic, and other applications by oral, intravenous, subcutaneous, intra muscular, inhalation, nasal, topical, ocular, and transdermal routes.

The invention discloses an alprostadil medium-and-long-chain lipid emulsion for injection and a preparation method thereof, belonging to the technical field of biological medicines. The lipid emulsion is composed of the following components in parts by weight: 0.01-0.1 part of alprostadil, 10-100 parts of long-chain triglycerides, 10-100 parts of medium-chain triglycerides, 1-20 parts of phospholipids, 0.01-1 part of oleic acid, 5-20 parts of glycerol and 300-2500 parts of water for injection. The particle size of the lipid emulsion is 50-200 nm, the lipid emulsion has good stability while the pH value is 5.0-8.0, and the contents of degradation products including prostaglandin A1 and prostaglandin B1 of alprostadil measured by using an HPLC (High Performance Liquid Chromatography) method are respectively below 1%. Compared with traditional alprostadil long-chain lipid emulsions, aqueous-phase alprostadil is significantly decreased, so that the vascular stimulation is reduced, and the liver load is reduced, therefore, the lipid metabolism can be accelerated, and the triglyceride level of plasma can be reduced.